Randomized trial · people

Semaglutide (oral) did not slow early Alzheimer's in evoke trials

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In these two large trials, oral semaglutide did not slow early Alzheimer's disease, and its safety was in line with what has been seen in its other uses.

Kind
Randomized trial
Studied in
People
Number studied
3808
Published
2026
Journal
Lancet

What they tested

The team tested whether daily oral semaglutide could slow the worsening of early Alzheimer's disease compared with a placebo, a dummy pill.

How the study was done

Two randomized, double-blind, placebo-controlled phase 3 trials enrolled 3808 people aged 55-85 with amyloid-confirmed Alzheimer's disease and mild cognitive impairment or mild dementia, across 566 sites in 40 countries. People were assigned 1:1 to oral semaglutide 14 mg once daily (flexible dose) or placebo for up to 156 weeks, and the main result was measured at week 104.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

The main measure was CDR-SB, a dementia rating score where higher means worse, and by week 104 it had risen by about the same amount in both groups. In evoke, the score went up 2.3 on semaglutide and 2.3 on placebo, a gap of -0.08 points with a p-value of 0.57 and a 95% confidence interval running from -0.35 to 0.20. In evoke+, it went up 2.2 on semaglutide and 2.1 on placebo, a gap of 0.10 points with a p-value of 0.46 and a 95% confidence interval running from -0.17 to 0.38. Side effects that came up during treatment were seen in 1729 (91.2%) of 1896 people taking semaglutide and 1613 (84.8%) of 1902 taking placebo, and investigators linked five deaths to treatment: one on semaglutide and four on placebo.

What it doesn’t show

The trials tested only the 14 mg flexible dose of the oral form, in people with early, amyloid-confirmed Alzheimer's, and only 54 (2.8%) people in evoke+ had small vessel pathology. Both trials were stopped because of the negative result, and they were funded by Novo Nordisk.

The paper

Cummings et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026.

The compounds

More studies on Semaglutide (oral)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Semaglutide (oral)? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo